Trial reportHereditas2025
Clinical efficacy of acupoint application therapy combined with Kangyou Decoction in treating Helicobacter pylori infection with damp-heat syndrome of the middle Jiao.
Trial report in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThis study evaluated the clinical efficacy and safety of acupoint application of traditional Chinese medicine (TCM) combined with Kangyou Decoction in patients with Helicobacter pylori (Hp) infection presenting with damp-heat syndrome obstructing the middle jiao.
methodsA total of 416 patients with Hp infection and TCM-defined damp-heat syndrome of the middle jiao were enrolled and randomly assigned to a treatment group (n = 208) or a control group (n = 208). The control group received standard bismuth-containing quadruple therapy, while the treatment group received acupoint application of TCM combined with oral administration of Kangyou Decoction. Both groups underwent treatment for two weeks. Outcomes included Hp eradication rates, changes in TCM syndrome scores pre- and post-treatment, and the incidence of adverse reactions.
resultsFollowing two weeks of therapy, no statistically significant difference in Hp eradication rates was observed between the two groups (p > 0.05). Both groups demonstrated significant improvement in TCM syndrome scores (p < 0.05), with the treatment group showing a greater reduction compared to the control group (p < 0.05). The total effective rate in the treatment group was higher than that in the control group. Incidences of adverse reactions did not differ significantly between the groups (p > 0.05).
conclusionAcupoint application combined with Kangyou Decoction yielded comparable Hp eradication outcomes to bismuth quadruple therapy in patients with damp-heat syndrome of the middle jiao. The combined therapy demonstrated greater improvement in clinical symptoms with a favorable safety profile, supporting its potential for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.